Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03380026
Other study ID # RSLMG-17.10
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 13, 2017
Est. completion date December 13, 2020

Study information

Verified date October 2021
Source Rochester Skin Lymphoma Medical Group, PLLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two-arm, open-label study that aims to compare the incidence and severity of the most common adverse reactions, particularly contact dermatitis, when Valchlor is used alone or in conjunction with triamcinolone ointment 0.1% in early stage MF subjects (Stage IA and IB) for a period of 4 months.


Description:

Mechlorethamine hydrochloride, or most commonly known as nitrogen nitrogen mustard, was approved by the FDA in 2013 for the treatment of IA and IB Mycosis Fungoides. The most common side effect of Valchlor is a skin rash, which is routinely ameliorated with the application of topical corticosteroids, such as topical Triamcinolone. The main purpose of this study is to determine the efficacy of Triamcinolone in reducing side effects cause by Valchlor and further understand the nature of this skin rash. This is a split-face study, meaning that subjects will receive both therapies, but limit use to designated areas. Treatment lasts 4 months with follow ups at 5 and 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date December 13, 2020
Est. primary completion date August 3, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be eligible to receive Valchlor therapy. - Be at least of 18 years of age and ability to give informed consent - Have stage IA or IB CTCL - Subjects with histologic variants of Mycosis Fungoides such as folliculotropic, granulomatous slack skin, syringotropic MF, or large cell transformation ARE eligible. - A skin biopsy within the last 60 days before start of treatment. In cases with equivocal histological features, the diagnosis may be confirmed with clinicopathologic and/or genetic testing consistent with the National Comprehensive Cancer Network guidelines for Mycosis Fungoides. If sufficient tissue is not available to perform genetic testing, a new biopsy will be performed even if the subject has had a biopsy within 60 days of start of treatment. - Females of child bearing potential must agree to use two highly effective methods of contraception (strongly recommended that one of the two forms of contraception be non-hormonal such as condom plus spermicide, condom plus diaphragm with spermicide, or have a vasectomized partner) or use an intrauterine device until 30 days after the last day of drug administration. Perimenopausal women must be amenorrhoeic for at least 12 months to be considered of nonchildbearing potential. - Males with female partners of child bearing potential must agree to sexual abstinence or use two reliable forms of effective contraception simultaneously (strongly recommended that one of the two forms should be non-hormonal as described above) during the entire treatment period and 30 days after the last dose. - Must be able to comply with the study instructions, apply the study medication as directed, and attend all visits. - Willingness to avoid sun exposure and ultraviolet B light in areas to be treated. Exclusion Criteria: - Have been treated with topical mechlorethamine within 6 months in lesions followed during this study. - Have received any topical therapy directed against MF within 2 weeks of start of treatment in areas intended to be treated in this study. - Have received any systemic therapy (oral or injectables) within 3 weeks of start of treatment. - Not have any intercurrent illness or infection that would interfere with study participation - Known hypersensitivity to mechlorethamine or triamcinolone. - Breastfeeding, pregnancy, or intention to become pregnant.

Study Design


Intervention

Drug:
Triamcinolone
Apply up to three times daily on select lesions.
Valchlor 0.016 % Topical Gel
Apply valchlor nightly on select lesions.

Locations

Country Name City State
United States Rochester Skin Lymphoma Medical Group, PLLC Fairport New York

Sponsors (2)

Lead Sponsor Collaborator
Rochester Skin Lymphoma Medical Group, PLLC Rochester General Hospital

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Severity of Dermatitis Scoring Atopic Dermatitis (SCORAD) differences between lesions treated with Valchlor and Triamcinolone versus lesions treated with Valchlor only. SCORAD measures the extent and severity of dermatitis. The percentage of total body surface area (0-100) covered by a lesion is measured by an investigator, and this number corresponds to score "A." The intensity criteria are met by scoring erythema, edema/papulation, oozing/crusting, excoriation, xerosis, and thickness on a scale of 0-3 (0=none, 1=mild, 2=Moderate, 3=Severe). These values are summed to give a total score, "B." Subjective symptoms of pruritus and insomnia are then scored using visual analogue scales ranging from 0-10 (0=none, 10=worst imaginable), and the result of each is summed to give score "C". The final score is then calculated by the formula A/5 + 7B/2 + C. The lowest possible score is 0, and the highest possible score is 103. A higher score indicates a worse outcome.
A lower score would be a better outcome.
4 months
Other Efficacy of Valchlor vs Valchlor Plus Triamcinolone Efficacy of Valchlor therapy with Triamcinolone compared to Valchlor using a composite assessment of index lesion severity (CAILS). CAILS is an objective, quantitative, method to assess the extent of skin lesions. Skin lesions and erythema will be evaluated using CAILS. A Composite Assessment will be generated for each time point by a summation of the grades for each index lesion's erythema, scaling, plaque elevation, hypopigmentation or hyperpigmentation, and area of involvement. The index lesion grade at baseline will be divided into the grade at each subsequent study visit to determine the subject's response to treatment. Any ratio of the grade obtained at the visit vs. the one obtained at baseline that is >1.0 will indicate worsening of disease. 4 months
Primary Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring Incidence of moderate to severe contact dermatitis in patients treated concurrently with Triamcinolone 0.1% ointment versus those that are not. Dermatitis will be defined as a finding of cutaneous inflammatory reaction occurring as a result of treatment. This will be assessed by the SCORD (SCORing Dermatitis) tool and may be confirmed by biopsy of the specimen. Moderate to Severe Contact dermatitis is defined as >25 by SCORD. 4 months
Secondary Nature of Contact Dermatitis (Allergic Versus Irritant) The presence of allergic versus irritant dermatitis was characterized through skin biopsies sent for pathological review and patch testing. Subjects presenting to the clinic with dermatitis underwent patch testing to determine the presence of allergic vs. Irritant contact dermatitis, and at each case a biopsy sample was taken of the affected area to confirm the diagnosis. Patch testing was assessed by the investigator according to the International Contact Dermatitis Research Group scale, using the following for possible outcomes : ?+ indicates a doubtful reaction, 1+ indicates a weak reaction, 2+ represents a strong reaction, 3+ indicates an extreme reaction, and IR indicates an Irritant reaction. A higher score would indicate a worse outcome. 1-3+ reaction at the 96hr reading was considered positive for allergic contact dermatitis. 4 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Completed NCT00051012 - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Phase 4
Terminated NCT03789864 - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides N/A
Completed NCT01590732 - Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Phase 1
Recruiting NCT02848274 - ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting NCT05357794 - Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides Phase 2
Completed NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Phase 1
Recruiting NCT04960618 - Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome Phase 2
Completed NCT02883517 - Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Active, not recruiting NCT02953301 - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Phase 2
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Completed NCT02296164 - Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Recruiting NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides Phase 2
Completed NCT00038376 - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Phase 2
Completed NCT00168064 - Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Phase 2
Recruiting NCT05879458 - Ritlecitinib in CTCL Phase 2
Recruiting NCT05414500 - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Phase 1
Recruiting NCT05904522 - Histopathological Changes in Mycosis Fungoides N/A